Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy

Trial Profile

An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Evocalcet (Primary)
  • Indications Primary hyperparathyroidism
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 05 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 12 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top